CD22是相对分子质量约135 000的Ⅰ型跨膜糖蛋白，属于免疫球蛋白超家族中唾液酸黏附素家族成员之一，是B细胞受体的抑制性辅助受体，与B细胞的发生、分化以及功能密切相关。CD22特异性地表达于成熟B细胞和90% B淋巴瘤细胞表面。因此，抗CD22抗体药物治疗相关肿瘤已成为研究热点之一。此文就CD22的分子特征、功能以及靶向CD22治疗急性淋巴细胞白血病的研究进展做一综述。

CD22, a type Ⅰ transmembrane glycoprotein with ~135 000 relative molecular mass, is a member of the sialic acid adhesin family in the immunoglobulin superfamily. CD22 is an inhibitory auxiliary receptor for B cell receptors and closely related to the development, differentiation, and function of B cells. CD22 is specifically expressed on the surface of mature B cells and 90% of B lymphoma cells. Therefore, anti-CD22 antibody drug has become one of the hot spots in the treatment of related tumors. This article reviews the molecular characteristics and functions of CD22, as well as research progress of CD22-targeted therapy for acute lymphoblastic leukemia.